Aurinia Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aurinia Pharmaceuticals Inc. on August 18, 2023, regarding events occurring on that date. The company is incorporated in Alberta, Canada, and its common shares trade on The Nasdaq Stock Market LLC under the symbol AUPH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of two new directors to the Board of Directors effective August 18, 2023:
- Dr. Karen Smith
- Jeffrey A. Bailey
Both individuals entered into standard indemnification agreements with the Company. There are no family relationships between the new directors and existing directors or executives, and no transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
Compensation and Governance Details
As non-employee directors, Dr. Smith and Mr. Bailey are entitled to the following compensation:
- Annual Cash Retainer: $45,000 per year, payable quarterly in arrears.
- Standard Annual Equity: Aggregate grant date value of $200,000.
- Appointment Equity Award: Each director received an additional equity-based compensation award with an aggregate grant date value of $340,000 in connection with their appointment.
Investor Verification Checklist
- Verify the biographical details and qualifications of Dr. Karen Smith and Jeffrey A. Bailey in the attached press release (Exhibit 99.1).
- Confirm the total number of directors on the Board following these appointments to assess board composition.
- Review the Company's most recent Form 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Monitor future filings for any changes to the Board's compensation policies or additional equity grants.